Given the fact that AKT plays a key role in the cellular proliferation and survival and XB130 knockdown impedes AKT pathway, we concludes that XB130 downregulation may prohibit cell growth through inhibiting PI3K/AKT in prostate cancer. This evidence concerns the gene AFAP1L2 and prostate carcinoma.